Larimar Therapeutics (LRMR)

• Market cap: $247M
• 1 day: -4.5%
• 5 days: -7.76%
• 1 month: -7.19%
• 3 months: -11.87%
• 6 months: -21.22%
• Year to date: -14.41%
• 1 year: -9.17%
• 5 years: -84%
• 10 years: -96.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 65